Key Highlights:
- H1 2026 adjusted EBIT Margin held steady at 19.8%
- OrthoLite Acquisition contributed $29m of EBIT in the first half
- Reported Revenue up 19% to $837m, though organic growth was just 1%
- Net Debt stood at $842m, with Leverage of 2.3 times
- Medium-term Operating Margin target raised to 21%-23%
Coats Group plc (LSE:COA), the 250-year-old industrial thread maker that now also owns the world’s largest open-cell insole business, has spent 2026 holding a near-20% operating margin through a soft consumer backdrop while digesting the biggest acquisition in its modern history. Its shares, which touched a 52-week high of 97.2p on 6 March 2026 after record full-year results, have since drifted back to around 79p, according to market data on 2 September 2026, valuing the FTSE 250 group at roughly £1.5bn.
The question is whether the half-year results of 28 July 2026, showing flat organic sales, a small dip in adjusted Earnings Per Share and unchanged guidance, mark a trough in sentiment or a warning that the OrthoLite deal has raised the stakes at an awkward moment for apparel and footwear demand.
Half-year results: margins held at 19.8% as OrthoLite adds $29m of EBIT
On 28 July 2026 Coats reported results for the six months to 30 June 2026. Reported revenue rose 19% to $837m (H1 2025: $705m), almost entirely because of the OrthoLite acquisition completed on 31 October 2025; organic constant-currency growth was just 1%. Adjusted EBIT increased to $166m from $140m, although it fell 2% organically, and the adjusted EBIT margin was unchanged at 19.8%.
Adjusted profit before tax rose to $134.8m (H1 2025: $122.5m), but the enlarged share count following last year’s placing meant adjusted EPS slipped to 4.4 cents from 4.7 cents. Reported profit before tax fell to $104.3m from $111.0m after $28m of acquisition-related amortisation. Free Cash Flow was $30m (H1 2025: $38m), net debt stood at $842m and leverage was 2.3 times, against a target of 2.0 times or below by the year-end. The Interim Dividend was lifted 5% to 1.05 cents.
Apparel generated revenue of $486m (up 1% organically) at an 18.9% EBIT margin, while Footwear, which now houses OrthoLite, delivered $351m (flat organically) at 21.1%. OrthoLite contributed $29m of EBIT and remains on track for $5m of cost synergies in 2026, rising to more than $20m by 2028, with sales synergies of $40m-plus a year targeted by 2030.
Group chief executive David Paja said: “We continue to prove the resilience of our Business model by maintaining margins and generating good free cash flow during periods of adverse market conditions.” Full-year expectations were left unchanged, assuming a modest market decline in the second half, supported by $15m of incremental cost savings.
From thread to soles: what Coats does
Coats is a Tier 2 supplier to the global apparel and footwear industries, selling components to the factories that make garments and shoes for brands rather than to consumers. Its core products are industrial sewing and embroidery threads, zips, trims and structural footwear components, alongside performance threads used in airbags, seat belts and protective equipment. The group employs about 19,000 people, with Manufacturing concentrated in Asia.
The company reorganised into two divisions, Apparel and Footwear, for 2026, folding in the former Performance Materials unit, and exited its US Americas Yarns business in June 2025. The Footwear division was transformed by OrthoLite, acquired for an initial Enterprise value of $770m, or 10 times EBITDA. OrthoLite supplies more than 500 million pairs of open-cell foam insoles a year to around 550 brands and held roughly 36% of its addressable market at the time of the deal. Coats’ stated ambition is to become a “super tier 2” supplier treated as a strategic partner rather than a Commodity vendor.
2025 full-year results: record profit and upgraded targets
Full-year results for the year to 31 December 2025, published on 5 March 2026, showed revenue of $1,465m, up 2% reported and flat organically, and adjusted EBIT of $290m, up 3% organically, at a margin of 19.8%. Reported operating profit was $241m (2024: $224m). Adjusted EPS fell to 9.3 cents from 9.7 cents because of the Equity issued to help fund OrthoLite, while reported EPS edged up to 6.8 cents from 6.7 cents.
Coats (LSE:COA) described free cash flow of $160m as a record. Net debt excluding leases rose to $815m from $449m following the acquisition, leaving pro-forma leverage at 2.2 times, and the total dividend rose 5% to 3.28 cents per share. Alongside the results, the board upgraded its medium-term framework to revenue growth above 5% a year through the cycle, an operating margin of 21% to 23% (previously 19% to 21%), cumulative five-year free cash flow of around $1bn (previously $750m) and EPS growth of more than 10% a year. Mr Paja called 2025 “transformational”.
What could drive the stock next?
The most obvious catalyst is delivery on the second-half weighting. Management has guided to “good year-on-year earnings growth” and strong free cash flow for 2026, and the market will want evidence in the autumn trading update that cost recovery and the $15m of savings are flowing through. Bringing leverage to two times or below by December would remove a question mark that has hung over the Balance Sheet since the deal.
OrthoLite is the growth engine investors are being asked to trust. The four-month trading update flagged lower pro-forma revenue because of a strong comparative and temporary capacity constraints in Indonesia, so any recovery there would support the case. Coats also continues to gain share, reaching about 27% in Apparel and 30% in Footwear in 2025, while recycled-thread revenue rose 43% to $554m. The arrival of Tim Cobbold, chair of Spirax Group, as Coats chair on 1 August 2026 may bring fresh scrutiny of Capital allocation, including the Buybacks referenced in the group’s framework.
Coats’ fortunes remain tied to the order books of brands and retailers. The 20 May 2026 trading statement showed Footwear revenue down 4% organically in the first four months of the year, and a deeper destocking cycle would hit both thread and insole volumes. Tariff uncertainty and Middle East tensions have raised freight and input-cost volatility, and recovering those costs through pricing depends on customer negotiations that tend to lag.
Leverage of 2.3 times is higher than in recent years, and integration costs are estimated at $35m over the programme. Execution risk in Indonesia, where OrthoLite’s first footprint optimisation is planned, is real. Adjusted EPS fell in both 2025 and the first half of 2026 owing to dilution, so the equity story rests on synergies arriving on schedule. Coats also reports in US dollars while its shares trade in sterling, so currency swings can distort returns for UK investors.
Coats enters the final third of 2026 with unchanged guidance and a clear target list: leverage below two times, $5m of OrthoLite synergies and a return to organic growth in Footwear. The share price retreat from the March high suggests the market is weighing softer Demand more heavily than the upgraded medium-term targets. The autumn trading statement, and the trajectory at OrthoLite’s Indonesian plants, will show whether the “overlooked” label is deserved or whether caution is warranted.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...